You are here: Industry Insights > AstraZeneca

News List

Vaxzevria has similar safety profile to mRNA COVID-19 vaccines, finds study europeanpharmaceuticalreview
July 29, 2021
New studies show rates of blood clots were similar following vaccination with Vaxzevria and Comirnaty®, plus rates of rare blood clots are lower after the second Vaxzevria dose.
Study shows AZ’s COVID-19 jab did not increase the rate of rare blood clots after second dose pharmatimes
July 29, 2021
AstraZeneca’s COVID-19 vaccine – Vaxzevria – did not increase the rate of rare blood clots with low platelets after the second dose, according to a new study.
HUTCHMED and AstraZeneca Begin Phase II Trial of ORPATHYS® in Gastric Cancer americanpharmaceuticalreview
July 29, 2021
HUTCHMED and AstraZeneca PLC have initiated a Phase II study of ORPATHYS® (savolitinib), an oral, potent, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric ...
AstraZeneca and Regeneron to Research, Develop and Commercialize Medicines for Obesity americanpharmaceuticalreview
July 28, 2021
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.
AZ says its COVID-19 vaccine protects against severe disease caused by variants pharmatimes
July 26, 2021
AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.
AstraZeneca concludes Alexion acquisition for $39bn pharmaceutical-technology
July 23, 2021
AstraZeneca has concluded the acquisition of US-based biopharmaceutical company Alexion Pharmaceuticals for a total consideration of $39bn or $175 per share.
AstraZeneca Completes Acquisition of Alexion americanpharmaceuticalreview
July 22, 2021
AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
PM wants review of AstraZeneca age advice firstwordpharma
July 22, 2021
Australia's expert immunisation panel has been urged to consider expanding the age recommendation for AstraZeneca's COVID-19 vaccine to people aged under 60, as reported This is Money on Wednesday.
Two doses of Pfizer, AstraZeneca shots effective against Delta variant, study finds firstwordpharma
July 22, 2021
Research published in the NEJM suggests two doses of Pfizer/BioNTech or AstraZeneca's COVID-19 vaccines are nearly as effective against the highly transmissible Delta variant as they are against the previously dominant Alpha variant.
Moderna to join S&P 500, shares jump after hours firstwordpharma
July 16, 2021
In a statement on Thursday, S&P Dow Jones Indices said Moderna will join the S&P 500 index as of the start of trading on July 21, replacing Alexion Pharmaceuticals, as reported by Investing.com.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page